These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 38481570)

  • 41. Synthetic biology regulation and governance: Lessons from TAPIC for the United States, European Union, and Singapore.
    Trump BD
    Health Policy; 2017 Nov; 121(11):1139-1146. PubMed ID: 28807332
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Shaping the science-industry-policy interface in synthetic biology.
    Gaisser S; Reiss T
    Syst Synth Biol; 2009 Dec; 3(1-4):109-14. PubMed ID: 19816806
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dual-Use Quickscan: A Web-Based Tool to Assess the Dual-Use Potential of Life Science Research.
    Vennis IM; Schaap MM; Hogervorst PAM; de Bruin A; Schulpen S; Boot MA; van Passel MWJ; Rutjes SA; Bleijs DA
    Front Bioeng Biotechnol; 2021; 9():797076. PubMed ID: 34957083
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Synthetic biology and occupational risk.
    Howard J; Murashov V; Schulte P
    J Occup Environ Hyg; 2017 Mar; 14(3):224-236. PubMed ID: 27754800
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ethical and social insights into synthetic biology: predicting research fronts in the post-COVID-19 era.
    Wang G; Kong Q; Wang D; Asmi F
    Front Bioeng Biotechnol; 2023; 11():1085797. PubMed ID: 37274167
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Black box no more: a scoping review of AI governance frameworks to guide procurement and adoption of AI in medical imaging and radiotherapy in the UK.
    Stogiannos N; Malik R; Kumar A; Barnes A; Pogose M; Harvey H; McEntee MF; Malamateniou C
    Br J Radiol; 2023 Dec; 96(1152):20221157. PubMed ID: 37747285
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Yeast 2.0-connecting the dots in the construction of the world's first functional synthetic eukaryotic genome.
    Pretorius IS; Boeke JD
    FEMS Yeast Res; 2018 Jun; 18(4):. PubMed ID: 29648592
    [TBL] [Abstract][Full Text] [Related]  

  • 48. New regulatory thinking is needed for AI-based personalised drug and cell therapies in precision oncology.
    Derraz B; Breda G; Kaempf C; Baenke F; Cotte F; Reiche K; Köhl U; Kather JN; Eskenazy D; Gilbert S
    NPJ Precis Oncol; 2024 Jan; 8(1):23. PubMed ID: 38291217
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Does Biotechnology Pose New Catastrophic Risks?
    DiEuliis D; Ellington AD; Gronvall GK; Imperiale MJ
    Curr Top Microbiol Immunol; 2019; 424():107-119. PubMed ID: 31463535
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Emerging regulatory challenges of next-generation synthetic biology.
    Sheahan T; Wieden HJ
    Biochem Cell Biol; 2021 Dec; 99(6):766-771. PubMed ID: 34559974
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Politics by Automatic Means? A Critique of Artificial Intelligence Ethics at Work.
    Cole M; Cant C; Ustek Spilda F; Graham M
    Front Artif Intell; 2022; 5():869114. PubMed ID: 35910189
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Challenges for the European governance of synthetic biology for human health.
    Douglas CM; Stemerding D
    Life Sci Soc Policy; 2014 Dec; 10():6. PubMed ID: 26085442
    [TBL] [Abstract][Full Text] [Related]  

  • 53. China's evolving biosafety/biosecurity legislations.
    Cao C
    J Law Biosci; 2021; 8(1):lsab020. PubMed ID: 34221436
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Beyond Cost-Benefit Analysis in the Governance of Synthetic Biology.
    Wallach W; Saner M; Marchant G
    Hastings Cent Rep; 2018 Jan; 48 Suppl 1():S70-S77. PubMed ID: 29453841
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Your Robot Therapist Will See You Now: Ethical Implications of Embodied Artificial Intelligence in Psychiatry, Psychology, and Psychotherapy.
    Fiske A; Henningsen P; Buyx A
    J Med Internet Res; 2019 May; 21(5):e13216. PubMed ID: 31094356
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Working with bacteria and putting bacteria to work: The biopolitics of synthetic biology for energy in the United Kingdom.
    McLeod C; Nerlich B; Mohr A
    Energy Res Soc Sci; 2017 Aug; 30():35-42. PubMed ID: 28920015
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Artificial Intelligence-Based Conversational Agents for Chronic Conditions: Systematic Literature Review.
    Schachner T; Keller R; V Wangenheim F
    J Med Internet Res; 2020 Sep; 22(9):e20701. PubMed ID: 32924957
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparative, collaborative, and integrative risk governance for emerging technologies.
    Linkov I; Trump BD; Anklam E; Berube D; Boisseasu P; Cummings C; Ferson S; Florin MV; Goldstein B; Hristozov D; Jensen KA; Katalagarianakis G; Kuzma J; Lambert JH; Malloy T; Malsch I; Marcomini A; Merad M; Palma-Oliveira J; Perkins E; Renn O; Seager T; Stone V; Vallero D; Vermeire T
    Environ Syst Decis; 2018 May; 38(2):170-176. PubMed ID: 37829286
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Biosafety Initiatives in BMENA Region: Identification of Gaps and Advances.
    Khan E; Ahmed N; Temsamani KR; El-Gendy A; Cohen M; Hasan A; Gastfriend H; Cole J
    Front Public Health; 2016; 4():44. PubMed ID: 27047912
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.